Vergelijking

Buserelin vs. Pasireotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

57982-77-1

396091-73-9

Molecuulmassa

1239.42 g/mol

1047.21 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Buserelin	Pasireotid
Duitsland	Op recept	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Buserelin

Volledige vermelding →

Pasireotid

Volledige vermelding →

Frequently asked questions

What is the difference between Buserelin and Pasireotid?: Buserelin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Buserelin or Pasireotid?: The highest available evidence level is "Humane RCT" for Buserelin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Buserelin and Pasireotid in Germany and the United States?: Duitsland: Buserelin — Op recept, Pasireotid — Op recept. Verenigde Staten: Buserelin — Niet goedgekeurd, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Buserelin

Pasireotid

Duitsland

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Buserelin and Pasireotid?

Buserelin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Buserelin or Pasireotid?

The highest available evidence level is "Humane RCT" for Buserelin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Buserelin and Pasireotid in Germany and the United States?

Duitsland: Buserelin — Op recept, Pasireotid — Op recept. Verenigde Staten: Buserelin — Niet goedgekeurd, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.